Showing results (431-440 of 468) with videos related to
Sort By:
Pageof 47
European Heart Journal|April 26, 2023
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trialsMuhammad Shahzeb Khan, Muhammad Shariq Usman, Khawaja M Talha, et al.European Heart Journal|May 24, 2019
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trialHarvey D White, Ph Gabriel Steg, Michael Szarek, et al.Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.Circulation|September 3, 2019
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary SyndromesMatthew T Roe, Qian H Li, Deepak L Bhatt, et al.Lancet (London, England)|August 20, 2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trialStephen D Wiviott, Harvey D White, E Magnus Ohman, et al.Journal of the American College of Cardiology|March 23, 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES TrialJ Wouter Jukema, Michael Szarek, Laurien E Zijlstra, et al.Circulation. Cardiovascular Quality and Outcomes|March 1, 2012
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS TrialMatthew T Roe, Jennifer A White, Padma Kaul, et al.Journal of the American College of Cardiology|April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.European Heart Journal|December 6, 2015
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndromeMatthew T Roe, Derek D Cyr, Debra Eckart, et al.Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.Pageof 47